Use in Specific Populations Pregnancy: Advise females of potential risk to a fetus especially during the second and third trimesters Lactation: FARXIGA is not recommended when breastfeeding FARXIGA is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular (CV) disease or multiple CV risk factors to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus
This will help you keep the weight off
Many of the neuroprotective, neurodegenerative, psychiatric, and addiction-related applications discussed remain investigational, and no GLP-1 receptor agonist is currently approved by regulatory authorities for the treatment or prevention of Alzheimers disease, Parkinsons disease, depression, substance use disorders, or other neurological indications unless specifically stated otherwise
The remethylation pathway can be disrupted or blocked by deficiencies of folate and vitamin B12.7,9 The body can also use betaine as a methyl donor in the remethylation pathway
